Discover
ANAB
AnaptysBio, Inc.
45.95
2 x 33.85
2 x 59.16
bid
ask
-
0.26
0.56%
2 @ 07:44 PM
45.76 -0.19 (0.41%)
| Ytd | 42.17% | |
| 1y | 116.95% |
45.81
day range
47.19
20.91
52 week range
69.81
| Open | 46.11 | Prev Close | 46.21 | Low | 45.81 | High | 47.19 | Mkt Cap | 1.37B |
| Vol | 495.67K | Avg Vol | 565.82K | EPS | -0.96 | P/E | N/A | Forward P/E | 9.07 |
| Beta | 0.45 | Short Ratio | 12.32 | Inst. Own | 105.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 54.52 | 200-d Avg | 49.12 | 1yr Est | 87.25 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-03 | 2026-09 | -1.84 | N/A | N/A | N/A |
| 2026-09-21 | 2026-06 | 5.11 | 5.11 | N/A | N/A |
| 2026-05-12 | 2026-03 | -0.32 | -1.84 | -1.52 | -475.00% |
| 2026-03-03 | 2025-12 | 0.89 | 1.58 | 0.69 | 77.53% |
| 2025-11-04 | 2025-09 | -1.06 | 0.52 | 1.58 | 149.06% |
| 2025-08-07 | 2025-06 | -1.5 | -1.34 | 0.16 | 10.67% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-09-30 | JP Morgan | Upgrade | Overweight | Overweight |
| 2026-09-24 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-09-23 | Leerink Partners | Upgrade | Outperform | Outperform |
| 2026-08-25 | TD Cowen | Upgrade | Buy | Buy |
| 2026-08-24 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-13 | UBS | Upgrade | Buy | Buy |
Profile
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-01-01 | ECOR1 CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2026-03-26 | FAGA DANIEL R | Chief Executive Officer | 495.97K | Sale |
| 2025-06-12 | JAIN RITA | Director | 11.86K | Conversion of Exercise of derivative security |
| 2026-01-07 | LIZZUL PAUL F. | Officer | 42.09K | Sale |
| 2026-02-10 | LOUMEAU ERIC JOSEPH | Officer | 12.84K | Sale |
| 2026-01-14 | MARQUET MAGDA | Director | 9.93K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | EcoR1 Capital, LLC | 7.88M | 362.09M | 26.36% |
| 2026-06-29 | Blackrock Inc. | 1.84M | 84.73M | 6.17% |
| 2026-06-29 | Tang Capital Management, LLC | 1.33M | 61.15M | 4.45% |
| 2026-06-29 | State Street Corporation | 1.29M | 59.10M | 4.30% |
| 2026-06-29 | Vanguard Capital Management LLC | 906.23K | 41.64M | 3.03% |
| 2026-06-29 | Affinity Asset Advisors, Llc | 826.11K | 37.96M | 2.76% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-08-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 830.30K | 38.15M | 2.78% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 648.15K | 29.78M | 2.17% |
| 2026-08-30 | iShares Trust-iShares Russell 2000 ETF | 507.27K | 23.31M | 1.70% |
| 2026-07-30 | TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 263.84K | 12.12M | 0.88% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 237.03K | 10.89M | 0.79% |
| 2026-07-30 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 215.87K | 9.92M | 0.72% |